DE-Heilbronn-SLK
Welcome,         Profile    Billing    Logout  
 6 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Martens, Uwe
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics

Recruiting
3
882
Europe
Cytarabine, Daunorubicin, CPX-351
University of Ulm, Jazz Pharmaceuticals
Acute Myeloid Leukemia
06/27
06/27
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
10/25
06/33
KEYNOTE-D18, NCT05155254 / 2021-004594-32: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Active, not recruiting
3
407
Europe, US, RoW
IO102-IO103, Pembrolizumab
IO Biotech, Syneos Health, Merck Sharp & Dohme LLC
Metastatic Melanoma, Unresectable Melanoma
07/25
09/27
INJECTABL-1, NCT05688280 / 2022-000176-19: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

Active, not recruiting
1/2
42
Europe, US
1.0% IP-001 for Injection, IP-001
Immunophotonics, Inc., Immunophotonics Inc.
Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
02/25
02/25
NCT06607185: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Recruiting
1
750
Europe, Japan, US, RoW
LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Eli Lilly and Company
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
01/30
01/30
NCT05641545: IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients

Terminated
1
1
Europe
IVAC
SLK Kliniken Heilbronn GmbH
Advanced Renal Cell Carcinoma
09/24
09/24
NCT05112549: Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)

Recruiting
1
46
Europe
Nivolumab [Opdivo]
University Hospital Tuebingen
Leptomeningeal Disease
12/26
09/27
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project

Recruiting
N/A
50000
Europe
University of Ulm
Acute Myeloid Leukemia (AML), MDS/AML
12/44
12/44
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

Completed
N/A
499
Europe
iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG
Advanced Solid Tumors or Hematologic Malignancies
06/23
06/23
REALTRK, NCT04557813: Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion

Completed
N/A
88
Europe
iOMEDICO AG, Roche Pharma AG
NTRK Family Gene Mutation
12/24
12/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Martens, Uwe
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics

Recruiting
3
882
Europe
Cytarabine, Daunorubicin, CPX-351
University of Ulm, Jazz Pharmaceuticals
Acute Myeloid Leukemia
06/27
06/27
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
10/25
06/33
KEYNOTE-D18, NCT05155254 / 2021-004594-32: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Active, not recruiting
3
407
Europe, US, RoW
IO102-IO103, Pembrolizumab
IO Biotech, Syneos Health, Merck Sharp & Dohme LLC
Metastatic Melanoma, Unresectable Melanoma
07/25
09/27
INJECTABL-1, NCT05688280 / 2022-000176-19: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

Active, not recruiting
1/2
42
Europe, US
1.0% IP-001 for Injection, IP-001
Immunophotonics, Inc., Immunophotonics Inc.
Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
02/25
02/25
NCT06607185: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Recruiting
1
750
Europe, Japan, US, RoW
LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Eli Lilly and Company
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
01/30
01/30
NCT05641545: IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients

Terminated
1
1
Europe
IVAC
SLK Kliniken Heilbronn GmbH
Advanced Renal Cell Carcinoma
09/24
09/24
NCT05112549: Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)

Recruiting
1
46
Europe
Nivolumab [Opdivo]
University Hospital Tuebingen
Leptomeningeal Disease
12/26
09/27
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project

Recruiting
N/A
50000
Europe
University of Ulm
Acute Myeloid Leukemia (AML), MDS/AML
12/44
12/44
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

Completed
N/A
499
Europe
iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG
Advanced Solid Tumors or Hematologic Malignancies
06/23
06/23
REALTRK, NCT04557813: Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion

Completed
N/A
88
Europe
iOMEDICO AG, Roche Pharma AG
NTRK Family Gene Mutation
12/24
12/24

Download Options